Keyphrases
Mantle Cell Lymphoma
100%
Rituximab
78%
Follicular Lymphoma
59%
Diffuse Large B-cell Lymphoma (DLBCL)
58%
Relapsed or Refractory
56%
Progression-free Survival
47%
Overall Survival
46%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
31%
Doxorubicin
31%
Lymphoma
31%
Maintenance Rituximab
29%
Prednisone
28%
Phase II Study
28%
Lymphoma Patients
28%
Chronic Lymphocytic Leukemia
28%
Bendamustine
27%
Clinical Trials
26%
Complete Response
25%
Cyclophosphamide
24%
Non-Hodgkin Lymphoma
23%
Hodgkin Lymphoma
21%
Bortezomib
20%
Overall Response Rate
20%
Bendamustine-rituximab
19%
Wisconsin
19%
Indolent non-Hodgkin Lymphoma
18%
R-CHOP
18%
Chemotherapy
18%
Oncological Networks
17%
Eastern Cooperative Oncology Group
16%
Confidence Interval
16%
Initial Treatment
15%
Network Studies
15%
High Risk
14%
Indolent Lymphoma
13%
Brentuximab Vedotin
12%
Lenalidomide
12%
Clinical Outcomes
12%
Frontline Therapy
12%
Duration of Response
12%
Ibrutinib
11%
Peripheral T-cell Lymphoma
11%
Older Patients
11%
Low Tumor Burden
11%
Chemoimmunotherapy
11%
Recent Advances
11%
Newly Diagnosed
11%
International Prognostic Index
11%
Previously Untreated
11%
Etoposide
10%
Medicine and Dentistry
Mantle Cell Lymphoma
84%
Rituximab
78%
Diffuse Large B-Cell Lymphoma
52%
Overall Survival
51%
Progression Free Survival
44%
Non-Hodgkin Lymphoma
44%
Disease
41%
Follicular Lymphoma
39%
Oncology
37%
Clinical Trial
32%
Neoplasm
29%
Hodgkin's Lymphoma
25%
Bendamustine
25%
Doxorubicin
24%
B-Cell Chronic Lymphocytic Leukemia
23%
Vincristine
22%
B Cell
20%
Cyclophosphamide
20%
Prednisone
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Lymphocytic Lymphoma
15%
Arm
14%
Malignant Neoplasm
14%
Adriamycin Bleomycin Vinblastine Dacarbazine
13%
B-Cell Lymphoma
13%
Transplantation
12%
Peripheral T-Cell Lymphoma
12%
Positron Emission Tomography
12%
Biological Marker
11%
Ibrutinib
11%
Bortezomib
11%
Stem Cell Transplant
11%
Chemoimmunotherapy
10%
Drug Megadose
10%
Cytarabine
9%
Adverse Event
9%
Lenalidomide
9%
Autologous Stem Cell Transplantation
9%
Brentuximab Vedotin
9%
Phosphoinositide 3-Kinase
9%
Classical Hodgkin Lymphoma
9%
MALT Lymphoma
9%
Electrocorticography
8%
Hematologic Malignancy
8%
Hematopoietic Stem Cell
8%
T Cell
7%
Hazard Ratio
7%
Etoposide
7%
Cohort Analysis
7%
Positron Emission Tomography
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
99%
Mantle Cell Lymphoma
72%
Follicular Lymphoma
53%
Nonhodgkin Lymphoma
52%
Diffuse Large B Cell Lymphoma
47%
Disease
39%
Bendamustine
38%
Progression Free Survival
38%
Overall Survival
38%
Cyclophosphamide
29%
Vincristine
28%
Doxorubicin
26%
Prednisone
25%
Chronic Lymphatic Leukemia
24%
Clinical Trial
23%
Chemotherapy
23%
Neoplasm
22%
Bortezomib
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Remission
15%
Adverse Event
13%
Lymphocytic Lymphoma
12%
Malignant Neoplasm
12%
Hodgkin Disease
12%
Phosphatidylinositol 3 Kinase
10%
Etoposide
10%
Lenalidomide
9%
Ibrutinib
9%
Neutropenia
8%
Ibritumomab Tiuxetan
8%
B Cell Lymphoma
8%
Idelalisib
7%
Venetoclax
7%
Loncastuximab Tesirine
7%
Pharmacokinetics
7%
Peripheral T Cell Lymphoma
7%
Event Free Survival
7%
Tolerability
7%
Zanubrutinib
6%
Yttrium 90
6%
Duvelisib
6%
Survival Rate
6%
Combination Therapy
6%
Hematologic Malignancy
6%
Minimal Residual Disease
6%
Biological Marker
6%
Methotrexate
6%
Diarrhea
5%
Bruton Tyrosine Kinase
5%
Large Cell Lymphoma
5%